Clinical Trials

590 enrolled

Lung Neoplasms

NCT02135042 2026-04-03

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05050162 2026-04-03

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Phase 2/3 Suspended

1,714 enrolled

Carcinoma, Oropharyngeal Neoplasms

NCT04559139 2026-03-19

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

186 enrolled

Gallbladder Neoplasms

NCT07129993 2026-03-19

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

630 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07463313 2026-03-11

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

116 enrolled

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

NCT03178552 2026-03-09

B-FAST

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06236438 2026-02-23

LIVIGNO-4

840 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04619797 2026-02-03

SKYSCRAPER-06

542 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07365319 2026-01-26

TeLuRide-008

750 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05800015 2026-01-22

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

950 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

490 enrolled

HER2-positive Gastric Cancer

NCT06115499 2026-01-07

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

10 enrolled

Pancreatic Neoplasms

NCT06783140 2025-12-05

PLATINUM-CAN

10 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT02066220 2025-12-04

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

360 enrolled

CNS

Brain Neoplasms, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT04442022 2025-10-03

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

501 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06095141 2025-08-07

PTCA199-6

30 enrolled

Pancreatic Adenocarcinoma

NCT05893888 2025-06-15

Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma

40 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06214572 2025-04-11

RUGB

249 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT06923475 2025-04-11

NEODISCO

150 enrolled

Cholangiocarcinoma, Klatskin Tumor

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

700 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT01249352 2025-03-31

NICE

104 enrolled

Adenocarcinoma, Esophageal Neoplasms

NCT02867865 2025-03-13

POLCAGB

124 enrolled

Gallbladder Neoplasms

NCT06861777 2025-03-11

Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC

474 enrolled

Esophageal Squamous Cell Carcinoma

NCT01924819 2025-03-04

TOPGEAR

574 enrolled

Stomach Neoplasms

NCT06037980 2025-02-17

PURITY

300 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06123884 2025-02-10

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

526 enrolled

Phase 2/3 Enrolling by invitation

Uterine Cervical Neoplasms

NCT06755515 2025-01-01

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

510 enrolled

Uterine Cervical Neoplasms

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

520 enrolled 16 charts 3 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT01554397 2024-11-29

Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer

101 enrolled 13 charts

Carcinoma, Uterine Cervical Neoplasms

NCT05255653 2024-11-29

RAINBO

1,615 enrolled

Endometrial Neoplasms

NCT06288373 2024-10-30

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

440 enrolled

Uterine Cervical Neoplasms

NCT06138028 2024-07-24

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

90 enrolled

Esophageal Squamous Cell Carcinoma

NCT02923258 2024-06-20

Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer

224 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05057130 2024-04-01

Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors

Phase 2/3 Unknown

50 enrolled

Sarcoma

Bone Neoplasms, Neoplasms, Connective Tissue, Sarcoma, Osteosarcoma, Neoplasms, Connective and Soft Tissue

NCT06268327 2024-02-20

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

30 enrolled

Breast

Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

503 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04864782 2024-01-12

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Phase 2/3 Terminated

46 enrolled

Uterine Cervical Neoplasms

NCT03600831 2024-01-09

Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma

434 enrolled

Esophageal Squamous Cell Carcinoma

NCT05125055 2023-11-22

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

80 enrolled